OVERVIEW

GI Cancer: Sequential Treatment Planning in the Community Oncology Setting is organized by Med-IQ.

Released: 8/9/19
Expires: 8/8/20

Target Audience:
This activity is intended for community oncologists.

Maximum Credits: 1.5

Overview:
Join expert faculty for a 90-minute webcast filmed during a gastrointestinal oncology forum that includes didactic lectures and case-based presentations. This activity is designed to take participants through various decision points to better align clinical factors with treatment decisions in a way that confers optimal patient outcomes throughout the disease continuum; specifically, faculty focus on using biomarkers to determine appropriate treatment planning from first-line through subsequent lines of therapy in colorectal cancer, gastric cancer, and hepatocellular carcinoma.

Statement of Need:
Knowledge related to the genetic nature of gastrointestinal (GI) cancers—specifically metastatic colorectal cancer (CRC), gastric and gastroesophageal junction (GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC)—as well as the use of biomarkers in patients with these cancers when appropriate, is rapidly evolving, requiring community oncologists to stay abreast of emerging evidence to guide treatment planning. Evidence-based guidelines and ongoing research can provide frameworks for determining treatment selection and proper sequencing across multitudes of different combinations of chemotherapy, molecular targeted therapies, anti-angiogenic agents, and immunotherapies; however, the most effective selection and sequence of agents continues to be debated. Focused, contextual education can help community oncologists better understand the role of factors such as patient characteristics and anatomical and molecular profiles of tumors in determining first-line treatment and subsequent lines of therapy.

Learning Objectives:
Upon completion, participants should be able to:
• Use patient characteristics and biomarker profiles to inform treatment decisions for patients with advanced or metastatic gastric and GEJ cancer
• Select appropriate treatment regimens for patients with advanced or metastatic gastric and GEJ cancer that maximize the benefit of sequential lines of therapy
• Define the influence of molecular characteristics and primary tumor location on treatment effectiveness in patients with mCRC
• Optimally select and sequence treatments for patients with mCRC based on multiple clinical factors including molecular characteristics and primary tumor location
• Discuss the use of prognostic and predictive biomarkers including AFP in HCC
Identify patients with advanced HCC who would benefit from individualized treatment approaches

Modules:
First-Line Treatment of Metastatic Gastric/GEJ Adenocarcinoma
Time to complete: 13 minutes

Second-Line Treatment and Beyond: Metastatic Gastric/GEJ Adenocarcinoma
Time to complete: 26 minutes

Treatment of Newly Diagnosed Metastatic CRC
Time to complete: 13 minutes

Treatment Decisions in Relapsed/Recurrent Metastatic CRC
Time to complete: 8 minutes

Treatment Planning in the First-Line Setting in Advanced HCC
Time to complete: 5 minutes

Treatment Selection in Previously Treated Advanced HCC
Time to complete: 16 minutes

Note: To receive credit and a certificate, you must complete all of the modules.